BG Medicine Gets Nasdaq Warning | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said after the close of the market Friday that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with one of the requirements for continued listing.

Specifically, Nasdaq said that the firm's market value of its listed securities had closed below the minimum $50 million required for continued listing for the 30 days leading up to Dec. 10. BG has until June 10, 2013, to regain compliance with the rule.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.